 | | |
 | ||
 | Koate DVI | |
| Plasbumin %25 | |
| Plasbumin %20 | |
| Gamimune N %5 | |
| Gamimune N %10 | |
| Bay Rho D | |
| Liberate | |
| Alba %20 | |
| Bay Rho D - Anti D Ig | |
| Bay Hep B - Hepatit B Ig | |
| Bay Tet -Tetanus Ig | |
 | Bay Rab - Hydrophobia Ig | |
 | General Information | |
 | ||
 | ||
 | ||
Products
Biological Products Bay Rab - Hydrophobia Ig Genel Bilgi
 |
Human Varicella Zoster Immunoglobulin (250mg) |
Qualitative and Quantitative Composition
Human Varicella Zoster Immunoglobulin (250mg)
Pharmaceutical Form
Liquid for inramuscular injection
Therapeutic Indications
Usage: For the prophlaxis of non-immune individuals exposed to Varicella or Zoster.
Human Varicella Zoster Immunoglobulin (VZIG) is indicated for patients in the following groups who have had significant exposures to Varicella or Zoster;
1. Patients receiving corticosteroid or immuno-suppressive treatment, including general radiation.
2. Patients suffering from malignant conditions such as lymphoma, leukemia, congenital or primary immuno-deficiency or where the normal immunological mechanism may be impaired whatever their original antibody status.
3. Premature infants whose mother lacks a prior history of Varicella.
4. Premature infants born before 208 weeks gestation or with a birth weight less than 1000g regardless of maternal history of Varicella.
5. Newborn babies who develop Varicella from 5 days before birth to 28 days after delivery.
6. Pregnant contacts.
The following are considered as significant exposures to Varicella or Zoster.
a. Continuous household contact.
b. Playmate contact (>1 hour play, indoors).
c. Hospital contact (shared 2 or 4 bedded room, adjacent beds or prolonged face to face contact).
d. Newborn contact (as in indication (5) above).
Posology and Method of Administration
Varicella-Zoster Immunoglobulin is for intramuscular use only and must not be administered intravenously.
The dosage for prevention of infection in all at-risk individuals varies with body weight. The recommended dosages are as follows;
Age
0-5 years 1 vial (250 mg)
6-10 years 2 vials (500 mg)
11-14 years 3 vials (750 mg)
15 years or more 4 vials (1000 mg)
The appropriate dosage should be administered as soon as possible, but in all cases, the product must be administered not later than than ten days after exposure.
The duration of protection after VZIG administration is unknown but if re-exposure occurs more than three weeks after a previous dose of Varicella-Zoster immunoglobulin, the patient should receive an additional full dose.
